3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High

Johnson & Johnson is presented as a long-term buy supported by a diversified drug pipeline, including Phase 3 multiple-myeloma candidate ramantamig with estimated peak annual sales of $1 billion-$5 billion. Its recently cleared Ottava robotic surgery platform targets a largely underpenetrated market, with fewer than 8% of relevant soft-tissue procedures performed robotically. The company also offers a 2.0% forward dividend yield versus 1.1% for the S&P 500 and has raised its dividend for 64 consecutive years, although biosimilar competition and government drug-price negotiations remain headwinds.

Analysis

The investable issue is not whether JNJ can participate in surgical robotics, but whether Ottava can earn enough installed-base density to offset price and utilization advantages held by ISRG. Capital equipment sales are low-margin entry points; the value accrues over years through instruments, service, training, and surgeon workflow lock-in. Near term, a credible second platform could modestly pressure ISRG placement economics and hospital contracting, but it is unlikely to impair ISRG’s recurring-revenue moat within the next 12-24 months absent evidence of materially faster procedure adoption or conversion at major IDNs.

JNJ’s pharmaceutical diversification reduces single-asset cliff risk, but it can also mask a more difficult earnings-quality question: whether new-product growth is sufficiently profitable and rapid to cover pricing pressure, biosimilar erosion, and launch investment. The article’s pipeline revenue ranges are company estimates rather than probability-adjusted forecasts; investors should demand trial readouts, label breadth, and reimbursement evidence before capitalizing peak-sales claims. Over 1-3 months, the stock’s defensive multiple and income bid limit downside in a risk-off tape; over 6-18 months, relative returns hinge on whether Innovative Medicine growth beats the drag from mature franchises.

Contrarian view: the market may be over-crediting Ottava as a standalone growth option while under-crediting ISRG’s installed-base economics. Robotic penetration can expand without meaningful share transfer, particularly if hospitals use a second system for procurement leverage rather than procedure migration. The cleaner relative setup is therefore JNJ as a defensive diversified-healthcare holding, not a directional short on ISRG; a durable ISRG de-rating requires visible slowdown in procedures, instruments per procedure, or system placements—not merely a new competitor clearance.

Key Decisions for Investors

• Maintain or initiate a 6-12 month long JNJ versus XLV: use JNJ as defensive healthcare exposure if Innovative Medicine organic growth remains above consensus and MedTech growth accelerates. Risk/reward is moderate rather than asymmetric; exit or reduce on a guidance cut tied to pricing/biosimilar pressure or a material adverse litigation reserve development.
• Do not short ISRG solely on Ottava. Set an alert for two consecutive quarters of procedure-growth deceleration, weaker recurring-revenue growth, or placement commentary citing competitive displacement; only then evaluate a 3-6 month ISRG put spread or long JNJ/short ISRG pair.
• Ahead of the next 2-3 earnings cycles, monitor Ottava placements, utilization, instrument attach rates, and named health-system adoption—not clearance headlines. A meaningful initial placement base without corresponding utilization would be a negative margin signal for JNJ, as launch and training expense would precede recurring revenue.
• Treat pipeline upside as optionality, not base-case earnings. Add to JNJ only after independently verifiable late-stage data or regulatory milestones improve probability-weighted value; failed pivotal data, narrower-than-expected labels, or reimbursement friction would falsify the incremental-growth thesis.